Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
February 15 2017 - 8:00AM
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company
focused on developing innovative oral treatment alternatives for
use in men’s and women’s health, today announced the promotion of
Gregory Bass to the newly created position of Executive Vice
President and Chief Commercial Officer reporting to Dr. Mahesh
Patel, President and Chief Executive Officer. Mr. Bass will
be responsible for leading the commercialization of Lipocine’s
product candidates, including its testosterone replacement
franchise. He joined Lipocine in 2016 and has served as its
Vice President of Market Access since that time.
Mr. Bass has over 20 years of experience in pharmaceutical and
biopharmaceutical sales, marketing and market access with a
consistent track record of improving operating performance and
delivering value across a broad range of leadership roles in
therapeutic categories at Pfizer and Johnson & Johnson.
Mr. Bass received his bachelor’s degree in Biology from Brandeis
University in Waltham, MA.
“We are excited to have Mr. Bass on our team as we position the
Company for a post approval launch of our novel oral testosterone
product candidate for testosterone replacement therapy,” said Dr.
Mahesh Patel. “Additionally, Mr. Bass is a talented,
experienced and capable commercial leader and has extensive launch
experience that includes multiple billion dollar products.
Since joining Lipocine over a year ago, Mr. Bass has played a key
role in building out the commercial capabilities of Lipocine.”
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. Lipocine’s
clinical development pipeline includes three development programs
LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral
prodrug of testosterone containing testosterone undecanoate, is
designed to help restore normal testosterone levels in hypogonadal
men. LPCN 1021, was well tolerated and met the primary efficacy
end-point in Phase 3 testing, which utilized 24-hour
pharmacokinetic data for dose adjustments, and is currently being
studied in two additional Phase 3 clinical trials. LPCN 1111,
a novel oral prodrug of testosterone, originated with and is being
developed by Lipocine as a next-generation oral testosterone
product with potential for once-daily dosing and is currently in
Phase 2 testing. LPCN 1107, the potentially first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth, has been granted orphan drug
designation by the FDA. An End of Phase 2 meeting with the FDA has
been completed. For more information, please visit
www.lipocine.com.
Forward-Looking Statements
This release contains “forward looking statements” that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding Lipocine’s FDA review process relating
to its product candidates, clinical trials related to its product
candidates and the related FDA review process, the possible outcome
and timing of such clinical trials or FDA review process, the path
to approvability by the FDA , the potential uses and benefits of
our product candidates, and our product development efforts.
Investors are cautioned that all such forward-looking statements
involve risks and uncertainties, including, without limitation, the
risks that the FDA will not approve any of our products, risks
related to our products, expected product benefits not being
realized, clinical and regulatory expectations and plans,
regulatory developments and requirements, risks related to the FDA
approval process, the receipt of regulatory approvals, the results
and timing of clinical trials, patient acceptance of Lipocine’s
products, the manufacturing and commercialization of Lipocine’s
products, and other risks detailed in Lipocine’s filings with the
SEC, including, without limitation, its Form 10-K and other reports
on Forms 8-K and 10-Q, all of which can be obtained on the SEC
website at www.sec.gov. Lipocine assumes no obligation to update or
revise publicly any forward-looking statements contained in this
release, except as required by law.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com
Investors:
John Woolford
Phone: (443) 213-0506
john.woolford@westwicke.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2023 to Apr 2024